Research Article
Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China
Table 1
Baseline characteristics of SARS-CoV-2-infected patients.
| | Variables | Total patients () | WM treatment group () | TCM-WM treatment group () | |
| | Age (y) | | | | 0.769 | | Mean (SD) | | | | | | Range | | | | | | <18 | 3 (1.69%) | 2 (1.60%) | 1 (1.89%) | | | 18-24 | 11 (6.18%) | 8 (6.40%) | 3 (5.66%) | | | 25-49 | 95 (53.37%) | 66 (52.80%) | 29 (54.72%) | | | 50-64 | 59 (33.15%) | 42 (33.60%) | 17 (32.08%) | | | > =65 | 10 (5.61%) | 7 (5.60%) | 3 (5.66%) | | | Sex | | | | 0.855 | | Female | 109 (61.24%) | 76 (60.80%) | 33 (62.26%) | | | Male | 69 (38.76%) | 49 (39.20%) | 20 (37.74%) | | | Agglomerative epidemic | | | | 0.001 | | Generation I | 35 (19.66%) | 14 (11.20%) | 21 (39.62%) | | | Generation II | 73 (41.01%) | 62 (49.60%) | 11 (20.75%) | | | Generation III | 42 (23.60%) | 33 (26.40%) | 9 (16.98%) | | | Generation IV | 28 (15.73%) | 16 (12.80%) | 12 (22.64%) | | | Number of nucleic acid tests | | | | 0.005 | | The first time | 133 (74.72%) | 84 (67.20%) | 49 (92.45%) | | | The second time | 32 (17.98%) | 29 (23.20%) | 3 (5.66%) | | | The third time | 11 (6.18%) | 10 (8.00%) | 1 (1.89%) | | | The fourth time | 2 (1.12%) | 2 (1.60%) | 0 (0.00%) | | | Comorbidities | | | | 0.976 | | Cardiovascular and cerebrovascular diseases, cerebrovascular diseases | 20 (11.24%) | 15 (12.00%) | 5 (9.43%) | | | Endocrine system diseases | 12 (6.74%) | 9 (7.20%) | 3 (5.66%) | | | Digestive system disease | 8 (4.49%) | 5 (4.00%) | 3 (5.66%) | | | Respiratory system diseases | 4 (2.25%) | 3 (2.40%) | 1 (1.89%) | | | Other disease | 4 (2.25%) | 2 (1.60%) | 2 (3.77%) | | | Signs and symptoms at admission | | | | 0.661 | | Fever | 136 (76.40%) | 97 (77.60%) | 39 (73.58%) | | | Cough | 90 (50.56%) | 68 (54.40%) | 22 (41.51%) | | | Shortness of breath | 29 (33.15%) | 25 (20.00%) | 4 (7.55%) | | | Muscle ache | 18 (10.11%) | 14 (11.20%) | 4 (7.55%) | | | Chest X-ray and CT findings | | | | 0.024 | | Bilateral pneumonia | 122 (68.54%) | 82 (65.60%) | 40 (75.47%) | | | Unilateral pneumonia | 40 (22.47%) | 27 (21.60%) | 13 (24.53%) | | | No abnormal density shadow | 16 (8.99%) | 16 (12.80%) | 0 (0.00%) | | | Clinical outcome | | | | 1.000 | | Remained in hospital | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | | | Discharged | 178 (100.00%) | 125 (100.00%) | 53 (100.00%) | | | Died | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | |
|
|
Abbreviation: SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; BMI: body mass index; ECMO: extracorporeal membrane oxygenation.
|
